{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:05:59Z","timestamp":1789049159418,"version":"build-2803163510"},"reference-count":88,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Psoriasis vulgaris is a chronic immune-mediated inflammatory disease in which treatment response is assessed using clinical indices such as the Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI), despite their limited ability to capture systemic inflammation and underlying immunological activity. This narrative review aims to summarize current evidence on inflammatory biomarkers for monitoring treatment response and to evaluate their potential clinical utility. A structured, non-systematic literature search was performed in April\u2013May 2026 across PubMed, Cochrane Library, Scopus, and ClinicalTrials.gov, focusing primarily on literature published during the preceding 10 years, with selected earlier studies being retained when directly relevant. Emerging data indicate that multiple biomarker domains may reflect therapeutic outcomes, including cytokines and chemokines, acute-phase proteins, complete-blood-count (CBC)-derived inflammatory indices, genetic markers, micro(mi)RNAs, metabolomic and lipidomic profiles, and tissue-based markers. These biomarkers may serve as severity-associated, baseline-predictive, pharmacodynamic, or prognostic markers, and these roles should not be interpreted interchangeably. Nevertheless, discrepancies between biomarker dynamics and clinical improvement occur, reflecting the partial dissociation between local and systemic inflammation, disease heterogeneity, and differences in response kinetics. Although inflammatory biomarkers provide a biologically grounded framework for assessing treatment response, their clinical implementation remains limited. Further large-scale, standardized studies are required to validate candidate markers and support the development of integrated, multi-omics approaches for personalized management.<\/jats:p>","DOI":"10.3390\/ijms27167221","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T17:01:35Z","timestamp":1786640495000},"page":"7221","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inflammatory Biomarkers for Assessing Treatment Response in Psoriasis: A Narrative Review"],"prefix":"10.3390","volume":"27","author":[{"given":"Julia Alicja","family":"Lewandowska","sequence":"first","affiliation":[{"name":"Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, University of Warmia and Mazury, 10-719 Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8372-0438","authenticated-orcid":false,"given":"Agnieszka","family":"Owczarczyk-Saczonek","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, University of Warmia and Mazury, 10-719 Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6286-0693","authenticated-orcid":false,"given":"Bogus\u0142aw","family":"Nedoszytko","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, 80-214 Gdansk, Poland"},{"name":"Department of Medical Laboratory Diagnostics-Farhenheit Biobank BBMRI.pl, Medical University of Gdansk, Debinki Street 7, 80-211 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2337264","DOI":"10.1080\/09546634.2024.2337264","article-title":"Characterization of psoriasis patients in special body areas: Real-world evidence from the Chinese Psoriasis Standardized Diagnosis and Treatment Center","volume":"35","author":"Gao","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12016-024-08991-7","article-title":"The Immunology of Psoriasis\u2014Current Concepts in Pathogenesis","volume":"66","author":"Sieminska","year":"2024","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_4","first-page":"3188","article-title":"Interleukin-21 is associated with the severity of psoriasis vulgaris through promoting CD4+ T cells to differentiate into Th17 cells","volume":"8","author":"Wang","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kimak-Pielas, A., Robak, E., Zajdel, R., and \u017bebrowska, A. (2025). The Relationship Between Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune-Inflammation Index Markers and Response to Biological Therapy in Patients with Psoriasis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26083868"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Morariu, S.-H., Cotoi, O.S., Tiuc\u0103, O.M., Baican, A., Gheuc\u0103-Solov\u0103stru, L., Decean, H., Brihan, I., Silaghi, K., Biro, V., and \u0218erban-Pescar, D. (2024). Blood-Count-Derived Inflammatory Markers as Predictors of Response to Biologics and Small-Molecule Inhibitors in Psoriasis: A Multicenter Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13143992"},{"key":"ref_7","first-page":"157","article-title":"Role of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, Mean Platelet Volume in Egyptian Patients with Psoriasis Vulgaris","volume":"27","author":"Hammad","year":"2020","journal-title":"Egypt. J. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2011.01.022","article-title":"Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis","volume":"66","author":"Robinson","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lee, H.-J., and Kim, M. (2023). Challenges and Future Trends in the Treatment of Psoriasis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713313"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"120633","DOI":"10.1016\/j.cca.2025.120633","article-title":"MicroRNA biomarkers in psoriasis","volume":"579","author":"Singh","year":"2026","journal-title":"Clin. Chim. Acta"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2147\/PTT.S531925","article-title":"Machine Learning-Driven Prediction Models for Brodalumab Therapeutic Effect and Response Speed in Plaque Psoriasis","volume":"15","author":"Peng","year":"2025","journal-title":"Psoriasis Targets Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jid.2019.09.023","article-title":"Early Quantification of Systemic Inflammatory Proteins Predicts Long-Term Treatment Response to Tofacitinib and Etanercept","volume":"140","author":"Tomalin","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/1346-8138.14308","article-title":"Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti-interleukin-17A agents","volume":"45","author":"Shibuya","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.5021\/ad.2019.31.6.601","article-title":"The Effects of Systemic Psoriasis Therapies on the C-Reactive Protein and the Neutrophil-Lymphocyte Ratio","volume":"31","author":"Demir","year":"2019","journal-title":"Ann. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1097\/CM9.0000000000002504","article-title":"Research progress of metabolomics in psoriasis","volume":"136","author":"Guo","year":"2023","journal-title":"Chin. Med. J."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Cruz, C.J.G., and Yang, C.C. (2023). Clinical application of serum biomarkers for detecting and monitoring of chronic plaque psoriasis. Front. Mol. Biosci., 10.","DOI":"10.3389\/fmolb.2023.1196323"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s00044-024-03355-4","article-title":"Integrating omics data for personalized medicine in treating psoriasis","volume":"34","author":"Ramchandani","year":"2025","journal-title":"Med. Chem. Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Sora, A., Hangan, T., Chirila, S.I., Gurgas, L., Botnarciuc, M., Daba, L.C., Cretu, A.M., Burlacu, I., Zamfirescu, M., and Petcu, A. (2025). Salivary Interleukins as Non-Invasive Biomarkers for Psoriasis: Advances and Challenges in Diagnosis and Monitoring. Medicina, 61.","DOI":"10.3390\/medicina61071180"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.abd.2023.03.002","article-title":"Elevated serum IL-6 levels predict treatment interruption in patients with moderate to severe psoriasis: A 6-year real-world cohort study","volume":"99","author":"Alves","year":"2024","journal-title":"An. Bras. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Andersen, C.S.B., Kvist-Hansen, A., Siewertsen, M., Enevold, C., Hansen, P.R., Kaur-Knudsen, D., Zachariae, C., Nielsen, C.H., Loft, N., and Skov, L. (2023). Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076111"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Cant\u00f3, E., del Prado, M.E., Vilarrasa, E., L\u00f3pez-Ferrer, A., Garc\u00eda Latasa de Aran\u00edbar, F.J., Ortiz, M.A., Gut, M., Mulet, M., Esteve-Codina, A., and Osuna-G\u00f3mez, R. (2025). Transcriptomic Identification of Immune-Related Hubs as Candidate Predictor Biomarkers of Therapeutic Response in Psoriasis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26178118"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Matei-Man, A.M., Vesa \u0218tefan, C., Pu\u0219ca\u0219, A.D., Or\u0103san, M.S., Homorozeanu, B., Candrea, E., and Mocan, T. (2025). Assessment of TNF-\u03b1, IL-12\/23, and IL-17 in Psoriasis: Only TNF-\u03b1 Reflects Clinical Response After 12 Weeks of Biologic Treatment. Curr. Issues Mol. Biol., 47.","DOI":"10.3390\/cimb47050368"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4103\/ijd.ijd_649_24","article-title":"The Role of TNF\u2013\u03b1, IFN\u2013\u03b3, and IL-6 in Guiding Treatment and Predicting Prognosis in the Treatment of Severe Plaque Psoriasis with Adalimumab","volume":"70","author":"Zhang","year":"2025","journal-title":"Indian J. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Medjedovic, L., Vi\u017elin, A., Andersch Bj\u00f6rkman, Y., Albertsson, A.-M., Raghavan, S., Gillstedt, M., and Osmancevic, A. (2026). Impact of Brodalumab on Serum Levels of IL-6, IL-17A, IFN-\u03b1, IFN-\u03b3, and TNF-\u03b1 in Patients with Psoriasis Who Failed Treatment with TNF-\u03b1 Inhibitors. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27010458"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ziolkowska-Banasik, D., Pastuszczak, M., Zawadzinska-Halat, K., Hadas, E., and Bozek, A. (2025). Serum IL-18\/IL-13 Ratio Predicts Super Response to Secukinumab in Patients with Psoriasis. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202506.1120.v1"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1038\/s41467-021-25066-9","article-title":"Enhanced NF-\u03baB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis","volume":"12","author":"Ale","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00228-017-2255-x","article-title":"Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis","volume":"73","author":"Indhumathi","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_28","first-page":"515","article-title":"Psoriasis Patients with Specific HLA-Cw Alleles and Lower Plasma IL-17 Level Show Improved Response to Topical Lindioil Treatment","volume":"15","author":"Lin","year":"2022","journal-title":"Pharmgenomics Pers. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.advms.2014.10.005","article-title":"Upregulation of the sFas\/sFasL system in psoriatic patients","volume":"60","author":"Baran","year":"2015","journal-title":"Adv. Med. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4274\/haseki.galenos.2023.9050","article-title":"Effect of Biological Therapy on Systemic Inflammatory Markers Among Patients with Chronic Plaque Psoriasis","volume":"61","author":"Kulakli","year":"2023","journal-title":"Med. Bull. Haseki"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Hagino, T., Saeki, H., and Kanda, N. (2023). Biomarkers and Predictive Factors for Treatment Response to Tumor Necrosis Factor-\u03b1 Inhibitors in Patients with Psoriasis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12030974"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/15569527.2023.2275020","article-title":"The effect of IL17 and IL23 inhibitors on hematological parameters and C-reactive protein in psoriasis patients","volume":"43","author":"Esen","year":"2024","journal-title":"Cutan. Ocul. Toxicol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e14606","DOI":"10.1111\/dth.14606","article-title":"Serum YKL-40 and IL 17 in Psoriasis: Reliability as prognostic markers for disease severity and responsiveness to treatment","volume":"34","author":"Khashaba","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Lee, S.H., Park, Y.-L., and Bae, Y. (2023). Gelsolin as a Potential Clinical Biomarker in Psoriasis Vulgaris. J. Clin. Med., 12.","DOI":"10.3390\/jcm12051801"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000475809","article-title":"Serum Human Beta-Defensin-2 Is a Possible Biomarker for Monitoring Response to JAK Inhibitor in Psoriasis Patients","volume":"233","author":"Jin","year":"2017","journal-title":"Dermatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1007\/s10067-024-07138-5","article-title":"Systematic analysis of serum peptidase inhibitor 3 in psoriasis diagnosis and treatment","volume":"43","author":"Xu","year":"2024","journal-title":"Clin. Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"120644","DOI":"10.1016\/j.cca.2025.120644","article-title":"Serum SCCA as a biomarker for assessing severity and monitoring treatment response in psoriasis","volume":"579","author":"Wei","year":"2026","journal-title":"Clin. Chim. Acta"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Niu, R., Li, Z., Jiang, W., Yang, Q., Duan, X., Sun, L., Cheng, Z., Huang, J., Li, L., and Ma, J. (2024). Pre-treatment plasma retinol binding protein 4 level and its change after treatments predict systemic treatment response in psoriasis patients. BMC Immunol., 25.","DOI":"10.1186\/s12865-024-00647-7"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s00296-024-05744-9","article-title":"Microfibrillar-associated protein 4 as a predictive biomarker of treatment response in patients with chronic inflammatory diseases initiating biologics: Secondary analyses based on the prospective BELIEVE cohort study","volume":"44","author":"Munk","year":"2024","journal-title":"Rheumatol. Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4103\/JEWD.JEWD_12_19","article-title":"Serum calprotectin as a predictive biomarker in the treatment of psoriasis vulgaris with methotrexate","volume":"16","author":"Hamza","year":"2019","journal-title":"J. Egypt. Women\u2019s Dermatol. Soc."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1007\/s10067-026-07981-8","article-title":"Evaluation of serum TWEAK levels and treatment response in psoriasis and psoriatic arthritis: A prospective comparative case\u2013control study of adalimumab and methotrexate","volume":"45","author":"Hegazy","year":"2026","journal-title":"Clin. Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2217\/bmm-2023-0425","article-title":"Longitudinal Change in CDC42 in Psoriasis: Correlation with dIsease Activity and Treatment Response","volume":"17","author":"Xu","year":"2023","journal-title":"Biomark. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Sugimoto, E., Matsuda, H., Shibata, S., Mizuno, Y., Koyama, A., Li, L., Taira, H., Ito, Y., Awaji, K., and Yamashita, T. (2023). Impact of Pretreatment Systemic Inflammatory Markers on Treatment Persistence with Biologics and Conventional Systemic Therapy: A Retrospective Study of Patients with Psoriasis Vulgaris and Psoriatic Arthritis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12083046"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ho\u0142drowicz, A., Zajdel, R., and \u017bebrowska, A. (2025). Blood-Count-Derived Inflammatory Biomarkers and Characterization of Super-Responder Profile in Psoriatic Patients Receiving Biological Treatment: A Single-Center Study. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262110770"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"536","DOI":"10.14744\/SEMB.2023.43569","article-title":"Could Blood Cell-Based Inflammatory Markers Be Used to Monitor Response to Biologic Therapy in Psoriasis?","volume":"57","author":"Kulakli","year":"2023","journal-title":"Sisli Etfal Hastan. Tip Bul."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Mortato, E., Marcelli, L., Panichelli, A., Talamonti, M., Gneo, V., Marrapodi, D., Di Raimondo, C., Bianchi, L., and Galluzzo, M. (2026). Long-Term Impact of Guselkumab on Systemic Inflammation Indices in Moderate-to-Severe Psoriasis. J. Clin. Med., 15.","DOI":"10.3390\/jcm15020439"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000545148","article-title":"Treatment of Plaque Psoriasis with Guselkumab Reduces Systemic Inflammatory Burden as Measured by Neutrophil\/Lymphocyte Ratio, Platelet\/Lymphocyte Ratio, and Monocyte\/Lymphocyte Ratio: A post hoc Analysis of Three Randomised Clinical Trials","volume":"241","author":"Kearney","year":"2025","journal-title":"Dermatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"74","DOI":"10.36849\/JDD.7525","article-title":"Blood Monocyte Count Can Predict Early Response to Secukinumab Therapy in Patients With Psoriasis","volume":"23","author":"Hadas","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1080\/14712598.2025.2604057","article-title":"Cell population data as predictive biomarkers for biologic therapy response in psoriasis","volume":"25","author":"Liu","year":"2025","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jid.2019.08.457","article-title":"High Levels of Platelet-Lymphocyte Complexes in Patients with Psoriasis Are Associated with a Better Response to Anti\u2013TNF-\u03b1 Therapy","volume":"140","author":"Moga","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/j.jid.2024.01.034","article-title":"Circulating Monocytes Are Predictive and Responsive in Moderate-to-Severe Plaque Psoriasis Subjects Treated with Apremilast","volume":"144","author":"Larson","year":"2024","journal-title":"J. Investig. Dermatol."},{"key":"ref_52","first-page":"SP231442","article-title":"Impact of TNF-\u03b1 and TNFR1B genes polymorphisms on disease susceptibility and predict response to anti-TNF therapy in psoriatic patients","volume":"23","author":"Abbas","year":"2020","journal-title":"Ann. Trop. Med. Public Health"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Pu\u0219ca\u0219, A.D., Morar, I.I., Vesa \u0218tefan, C., C\u0103tan\u0103, A., Pu\u0219ca\u0219, C., Ilie\u0219, R.F., and Orasan, R.-I. (2023). Association between IL-17F, IL-17RA Gene Polymorphisms and Response to Biological Drugs in Psoriasis and Beyond. Genes, 14.","DOI":"10.3390\/genes14051123"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Hamza, A., Elwafa, R.A.A., Ramadan, N., and Omar, S.S. (2021). IL17A (rs2275913 G>A) and IL17F (rs2397084 T>C) Gene Polymorphisms: Relation to Psoriasis Risk and Response to Methotrexate. Res. Sq.","DOI":"10.21203\/rs.3.rs-179340\/v1"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1159\/000448090","article-title":"IL17A and IL17F Gene Polymorphism Association with Psoriasis Risk and Response to Treatment in a Polish Population","volume":"232","author":"Ostasz","year":"2016","journal-title":"Dermatology"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Wang, C.-Y., Wang, C.-W., Chen, C.-B., Chen, W.-T., Chang, Y.-C., Hui, R.C.-Y., and Chung, W.-H. (2023). Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087329"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/bjd.21677","article-title":"Biomarkers of systemic treatment response in people with psoriasis: A scoping review","volume":"187","author":"Corbett","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Berna-Rico, E., Perez-Bootello, J., Abbad-Jaime de Aragon, C., and Gonzalez-Cantero, A. (2023). Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24129850"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.jaci.2018.11.038","article-title":"HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis","volume":"143","author":"Dand","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"632","DOI":"10.4103\/ijd.IJD_282_21","article-title":"HLA-Cw6 Status and Treatment Responses Between Psoriasis Patients","volume":"66","author":"Temel","year":"2021","journal-title":"Indian J. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/ced.13100","article-title":"HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment","volume":"42","author":"West","year":"2017","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"501165","DOI":"10.1016\/j.abd.2025.501165","article-title":"Evaluation of Tyrosine Kinase-2 (TYK2) signaling pathway gene expression and the presence of the single-nucleotide polymorphism rs12720356 in the peripheral blood of patients with severe psoriasis and loss of systemic treatment response","volume":"100","author":"Canabrava","year":"2025","journal-title":"An. Bras. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Connell, W.T., Hong, J., and Liao, W. (2022). Genome-Wide Association Study of Ustekinumab Response in Psoriasis. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.815121"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Ren, Y., Wang, L., Dai, H., Qiu, G., Liu, J., Yu, D., Liu, J., Lyu, C.-Z., Liu, L., and Zheng, M. (2022). Genome-wide association analysis of anti-TNF-\u03b1 treatment response in Chinese patients with psoriasis. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.968935"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Ioakeimidou, D., Zafiriou, E., Giannoulis, T., Kouvarou, O., Gerogianni, K., Bogdanos, D.P., Sarafidou, T., and Liadaki, K. (2025). A Genome-Wide Association Study in Psoriasis Patients Reveals Variants Associated with Response to Treatment with Interleukin-17A Pathway Inhibitors. Genes, 16.","DOI":"10.3390\/genes16101187"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/ced\/llae128","article-title":"ERAP1 and ERAP2 gene variants as potential clinical biomarkers of anti-interleukin-17A response in psoriasis vulgaris","volume":"49","author":"Kronborg","year":"2024","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Zachari, S., Liadaki, K., Planaki, A., Zafiriou, E., Kouvarou, O., Gerogianni, K., Giannoulis, T., Mamuris, Z., Bogdanos, D.P., and Moschonas, N.K. (2025). A Genome-Wide Association Study Identifying Novel Genetic Markers of Response to Treatment with Interleukin-23 Inhibitors in Psoriasis. Genes, 16.","DOI":"10.3390\/genes16101195"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/bjd.15005","article-title":"Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis","volume":"176","author":"Coenen","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Loft, N., Altintas, S., Al-Sofi, R., Isufi, D., Zachariae, C., Kaur-Knudsen, D., Nielsen, C.H., and Skov, L. (2025). The Association Between Genetics and Response to Treatment with Biologics in Patients with Psoriasis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26188998"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e15003","DOI":"10.1111\/exd.15003","article-title":"Association between several immune response-related genes and the effectiveness of biological treatments in patients with moderate-to-severe psoriasis","volume":"33","author":"Loras","year":"2024","journal-title":"Exp. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3897\/pharmacia.72.e171506","article-title":"Association of IL-1\u03b2 gene promoter polymorphisms and serum levels with etanercept response in Iraqi patients with moderate to severe psoriasis","volume":"72","author":"Jamaah","year":"2025","journal-title":"Pharmacia"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Membrive Jim\u00e9nez, C., P\u00e9rez Ram\u00edrez, C., S\u00e1nchez Mart\u00edn, A., Vieira Maroun, S., Arias Santiago, S.A., Ram\u00edrez Tortosa, M.d.C., and Jim\u00e9nez Morales, A. (2021). Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis. J. Pers. Med., 11.","DOI":"10.3390\/jpm11040293"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s13555-025-01610-z","article-title":"Drug Stratification Based on Real-World Evidence in Psoriasis: A Narrative Review","volume":"16","author":"Sindrup","year":"2026","journal-title":"Dermatol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/exd.13249","article-title":"Roles of microRNAs in psoriasis: Immunological functions and potential biomarkers","volume":"26","author":"Liu","year":"2017","journal-title":"Exp. Dermatol."},{"key":"ref_75","first-page":"367","article-title":"Understanding psoriasis: Role of miRNAs (Review)","volume":"9","author":"Timis","year":"2018","journal-title":"Biomed. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e14221","DOI":"10.1111\/dth.14221","article-title":"Insightful exploring of microRNAs in psoriasis and its targeted topical delivery","volume":"33","author":"Pradyuth","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s13555-024-01331-9","article-title":"Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort Study","volume":"15","author":"Diotallevi","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s13555-023-00931-1","article-title":"InflammamiR-146a and -155 Plasma Levels are Associated with Clinical Efficacy of Risankizumab Treatment in Psoriatic Patients: Pilot Study","volume":"13","author":"Diotallevi","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"353","DOI":"10.25122\/jml-2024-0264","article-title":"Is Mir-205 a possible biomarker for evaluating treatment response in psoriasis?","volume":"17","author":"Mihu","year":"2024","journal-title":"J. Med. Life"},{"key":"ref_80","first-page":"1","article-title":"Baseline Clinical and Metabolic Predictors of 52-Week Durability of Secukinumab Response in Moderate-to-Severe Plaque Psoriasis","volume":"19","author":"Wang","year":"2026","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Belli, R., Dattolo, A., Sampogna, F., Gubinelli, E., Lulli, D., Moretta, G., Scala, E., Sanna, L., Megna, M., and Cannizzaro, M.V. (2025). Leptin: A gender and obesity-related marker predictive of metabolic comorbidities and therapeutic response to anti-IL-23 biologic drugs in psoriatic patients. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1607312"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/jamadermatol.2025.0288","article-title":"Association of Obesity and Innate Immune Markers With Resistance to Biologic Therapy in Psoriasis","volume":"161","author":"Kim","year":"2025","journal-title":"JAMA Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jaci.2021.07.024","article-title":"Cytokine responses in nonlesional psoriatic skin as clinical predictor to anti-TNF agents","volume":"149","author":"Tsoi","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/15569527.2024.2380310","article-title":"The relationship between TNF-\u03b1, IL-1, IL-12, IL-17, IL-23, IL-36 expression and treatment response in psoriasis histopathologically and immunohistochemically","volume":"43","author":"Temiz","year":"2024","journal-title":"Cutan. Ocul. Toxicol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/cup.14729","article-title":"The Association of Interleukin-36 Staining Intensity and Response to Biologic Therapy in Patients With Psoriasis: A Retrospective Immunohistochemical and Chart Review Pilot Study","volume":"52","author":"Zhang","year":"2025","journal-title":"J. Cutan. Pathol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000068289","article-title":"Alteration of the Expression of Bcl-2, Bcl-x, Bax, Fas, and Fas Ligand in the Involved Skin of Psoriasis vulgaris following Topical Anthralin Therapy","volume":"16","author":"Yamamoto","year":"2003","journal-title":"Skin Pharmacol. Physiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2248318","DOI":"10.1080\/09546634.2023.2248318","article-title":"Potential biomarkers for psoriasis topical treatment by in-depth serum proteomics","volume":"34","author":"Cui","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Chicharro, P., Rodr\u00edguez-Jim\u00e9nez, P., Llamas-Velasco, M., Montes, N., Sanz-Garc\u00eda, A., Cibrian, D., Vara, A., G\u00f3mez, M.J., Jim\u00e9nez-Fern\u00e1ndez, M., and Mart\u00ednez-Fleta, P. (2020). Expression of miR-135b in Psoriatic Skin and Its Association with Disease Improvement. Cells, 9.","DOI":"10.3390\/cells9071603"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7221\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T17:02:09Z","timestamp":1786640529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":88,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ijms27167221"],"URL":"https:\/\/doi.org\/10.3390\/ijms27167221","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]}}}